FDA approves ibrutinib for previously treated MCLNovember 14, 2013Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin Lymphoma
Company suspends enrollment in drug trialsFebruary 21, 2013Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin Lymphoma
EMA recommends conditional approval of lymphoma drugFebruary 22, 2012Lymphoma & Plasma Cell Disorders
FDA grants accelerated approval for brentuximab vedotinAugust 22, 2011Lymphoma & Plasma Cell Disorders
CD19-redirected T cells induce remission in CLL patientsAugust 10, 2011Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
FDA warns of possible link between breast implants and ALCLJanuary 27, 2011Lymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
Denileukin diftitox has significant, durable responses in CTCLApril 1, 2010Lymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
ODAC votes against one leukemia, one NHL drugMarch 23, 2010Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders